U
Fresh2 Group Limited
FREHY
$0.10
-$0.02-16.67%
E
Sell
3/14/2023Downgrade
Fresh2 Group Limited (FREHY) was downgraded to E+ from D on 03/14/2023.
Fresh2 Group Limited (FREHY) was downgraded to E+ from D on 03/14/2023.
D
Sell
2/9/2023Upgraded
AnPac Bio-Medical Science Co., Ltd. (ANPC) was upgraded to D from E+ on 2/9/2023 due to an increase in the total return index.
AnPac Bio-Medical Science Co., Ltd. (ANPC) was upgraded to D from E+ on 2/9/2023 due to an increase in the total return index.
E
Sell
2/8/2023Downgrade
AnPac Bio-Medical Science Co., Ltd. (ANPC) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index and total return index.
AnPac Bio-Medical Science Co., Ltd. (ANPC) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index and total return index.
D
Sell
1/23/2023Upgraded
AnPac Bio-Medical Science Co., Ltd. (ANPC) was upgraded to D from D- on 1/23/2023 due to an increase in the valuation index, volatility index and total return index.
AnPac Bio-Medical Science Co., Ltd. (ANPC) was upgraded to D from D- on 1/23/2023 due to an increase in the valuation index, volatility index and total return index.
D
Sell
6/6/2022Upgraded
AnPac Bio-Medical Science Co., Ltd. (ANPC) was upgraded to D- from E+ on 6/6/2022 due to a significant increase in the solvency index, volatility index and total return index.
AnPac Bio-Medical Science Co., Ltd. (ANPC) was upgraded to D- from E+ on 6/6/2022 due to a significant increase in the solvency index, volatility index and total return index.
E
Sell
4/18/2022Downgrade
AnPac Bio-Medical Science Co., Ltd. (ANPC) was downgraded to E+ from D- on 4/18/2022 due to a significant decline in the solvency index, volatility index and total return index. The quick ratio declined from 0.72 to 0.21.
AnPac Bio-Medical Science Co., Ltd. (ANPC) was downgraded to E+ from D- on 4/18/2022 due to a significant decline in the solvency index, volatility index and total return index. The quick ratio declined from 0.72 to 0.21.
D
Sell
11/23/2021Upgraded
AnPac Bio-Medical Science Co., Ltd. (ANPC) was upgraded to D- from E+ on 11/23/2021 due to an increase in the valuation index.
AnPac Bio-Medical Science Co., Ltd. (ANPC) was upgraded to D- from E+ on 11/23/2021 due to an increase in the valuation index.
E
Sell
11/8/2021Downgrade
AnPac Bio-Medical Science Co., Ltd. (ANPC) was downgraded to E+ from D- on 11/8/2021 due to a decline in the volatility index and total return index.
AnPac Bio-Medical Science Co., Ltd. (ANPC) was downgraded to E+ from D- on 11/8/2021 due to a decline in the volatility index and total return index.
D
Sell
10/18/2021Upgraded
AnPac Bio-Medical Science Co., Ltd. (ANPC) was upgraded to D- from E+ on 10/18/2021 due to a major increase in the growth index, solvency index and valuation index. Total revenue increased 224.7% from $337.2 to $1.09M, the quick ratio increased from 0.35 to 0.72, and debt to equity declined from 2.65 to 0.57.
AnPac Bio-Medical Science Co., Ltd. (ANPC) was upgraded to D- from E+ on 10/18/2021 due to a major increase in the growth index, solvency index and valuation index. Total revenue increased 224.7% from $337.2 to $1.09M, the quick ratio increased from 0.35 to 0.72, and debt to equity declined from 2.65 to 0.57.
E
Sell
7/1/2021Downgrade
AnPac Bio-Medical Science Co., Ltd. (ANPC) was downgraded to E+ from D- on 7/1/2021 due to a decline in the total return index and volatility index.
AnPac Bio-Medical Science Co., Ltd. (ANPC) was downgraded to E+ from D- on 7/1/2021 due to a decline in the total return index and volatility index.
D
Sell
6/16/2021Upgraded
AnPac Bio-Medical Science Co., Ltd. (ANPC) was upgraded to D- from E+ on 6/16/2021 due to an increase in the volatility index and valuation index.
AnPac Bio-Medical Science Co., Ltd. (ANPC) was upgraded to D- from E+ on 6/16/2021 due to an increase in the volatility index and valuation index.
E
Sell
6/1/2021Downgrade
AnPac Bio-Medical Science Co., Ltd. (ANPC) was downgraded to E+ from D- on 6/1/2021 due to a noticeable decline in the growth index, efficiency index and volatility index. Net income declined 143.12% from -$1.84M to -$4.48M, earnings per share declined from -$0.1612 to -$0.3746, and total revenue declined 72.85% from $1.24M to $337.2.
AnPac Bio-Medical Science Co., Ltd. (ANPC) was downgraded to E+ from D- on 6/1/2021 due to a noticeable decline in the growth index, efficiency index and volatility index. Net income declined 143.12% from -$1.84M to -$4.48M, earnings per share declined from -$0.1612 to -$0.3746, and total revenue declined 72.85% from $1.24M to $337.2.
D
Sell
5/13/2021None
Fresh2 Group Limited (FREHY) was downgraded to D- from U on 05/13/2021.
Fresh2 Group Limited (FREHY) was downgraded to D- from U on 05/13/2021.
OTC
03/06/2025 1:13PM Eastern
Quotes delayed
